Your browser doesn't support javascript.
Leveraging publicly available coronavirus data to identify new therapeutic targets for COVID-19.
Sell, Stacy L; Prough, Donald S; Weisz, Harris A; Widen, Steve G; Hellmich, Helen L.
  • Sell SL; Department of Anesthesiology, The University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
  • Prough DS; Department of Anesthesiology, The University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
  • Weisz HA; Department of Anesthesiology, The University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
  • Widen SG; Department of Biochemistry and Molecular Biology, The University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
  • Hellmich HL; Department of Anesthesiology, The University of Texas Medical Branch at Galveston, Galveston, Texas, United States of America.
PLoS One ; 16(9): e0257965, 2021.
Article in English | MEDLINE | ID: covidwho-1443851
ABSTRACT
Many important questions remain regarding severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the viral pathogen responsible for COVID-19. These questions include the mechanisms explaining the high percentage of asymptomatic but highly infectious individuals, the wide variability in disease susceptibility, and the mechanisms of long-lasting debilitating effects. Bioinformatic analysis of four coronavirus datasets representing previous outbreaks (SARS-CoV-1 and MERS-CoV), as well as SARS-CoV-2, revealed evidence of diverse host factors that appear to be coopted to facilitate virus-induced suppression of interferon-induced innate immunity, promotion of viral replication and subversion and/or evasion of antiviral immune surveillance. These host factors merit further study given their postulated roles in COVID-19-induced loss of smell and brain, heart, vascular, lung, liver, and gut dysfunction.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Type of study: Observational study Limits: Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0257965

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / COVID-19 Drug Treatment Type of study: Observational study Limits: Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2021 Document Type: Article Affiliation country: Journal.pone.0257965